Immunochemistry services director joins PharmaNet

Will expand large molecule services at US firm

Chris Beaver has joined PharmaNet Development Group, a US provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, as director of immunochemistry services.

Beaver will lead the immunochemistry team within the firm’s bioanalytical laboratories and expand its large molecule services, including assay development and sample analysis for biomarker, ELISA, radioimmunoassays, immunogenicity and cell-based assays.

PharmaNet has two GLP-compliant bioanalytical laboratories located in Princeton, New Jersey and Quebec City, Canada.

You may also like

Regulatory

Standard proposed to clarify endotoxin testing for single-use systems

The guide will address variability when assessing bacterial endotoxins on large-scale pharmaceutical equipment
Research & Development

Weight loss drugs such as Ozempic may prevent stroke and reduce brain injury related complications

Three studies presented at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether
Regulatory

AlzeCure's pain project ACD440 granted orphan drug status in the US by the FDA

AlzeCure Pharma announces that the US Food and Drug Administration (FDA) has granted the company's application for orphan drug status for the clinical pain candidate drug ACD440
Research & Development

Amphista Therapeutics reaches research milestone and triggers a milestone payment from Merck

Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue degraders for oncology and immunology indications
Manufacturing

Precision under pressure

Why pharma manufacturing needs a harder look at weight control
Manufacturing

Gerresheimer achieves leadership status with A- CDP score

Sustainability progress earns strong rating for climate disclosure and emissions strategy
Research & Development

Qureight analyses of Insilico Medicine’s Phase IIa rentosertib data support preliminary efficacy results and future trial expansion

Qureight’s deep-learning image biomarkers and clinical data analytics platform used to analyse enrolled idiopathic pulmonary fibrosis (IPF) patient data, supporting efficacy outcome and expansion to larger global patient studies
Subscribe now